Cyclodextrin Publications

About Cyclodextrins

Molecular mechanism of cyclodextrin mediated cholesterol extraction

Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease

Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Systemic and renal lipids in kidney disease development and progression 

Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Lipid biology of the podocyte--new perspectives offer new opportunities.

Renal lipid metabolism and lipotoxicity. 

Cyclodextrins and Renal Disease

Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Cyclodextrin improves renal function in experimental alport syndrome.

Cyclodextrin protects podocytes in diabetic kidney disease.

Cyclodextrins and Non-renal Diseases

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.

Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.

Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.

Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.